[en] 41 patients with active rheumatoid arthritis entered a placebo-controlled double-blind randomised study in which 21 received slow intravenous injections (given in fractions over 10 min) of thymopentin (TP·5) 50 mg 3 times a week for 3 consecutive weeks and 20 received placebo in the same way. After 3 weeks of treatment the TP-5 group showed improvement (p<O' 05 or p<O: 01) in all but one of the clinical variables tested. There was improvement in the number of joints painful at rest, the number of joints painful on motion, scores for tenderness on pressure and swollen joints, severity of pain on awakening and morning stiffness, and right-hand grip strength; left hand grip strength remained unchanged. In the placebo group, only morning stiffness improved significantly.
Disciplines :
Rheumatology
Author, co-author :
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Goldstein (1971) Thymin a thymic polypeptide causing the neuromuscular block of myasthenia gravis. Ann NY Acad Sci 183:230-240.
Schlesinger, Goldstein (1975) The amino acid sequence ofthymopoietin II. Cell 5:361-365.
Goldstein, Schneid, Boyse, Schlesinger, van Wauve (1979) A synthetic pentapeptide with biological activity characteristics of the thymic hormone thymopoietin. Science 204:1309-1310.
Basch, Goldstein (1975) Antigenic and functional evidence for the in vitro inductive activity of thymopoietin on thymocyte precursors. Ann NY Acad Sci 249:290-297.
Scheid, Goldstein, Boyse (1978) The generation and regulation of lymphocyte population. Journal of Experimental Medicine 148:1727-1743.
Scheid, Goldstein, Boyse (1975) Differentiation of T cells in nude mice. Science 190:1211-1213.
Lau, Freestone, Goldstein (1980) Effect of thymopoietin pentapeptide on autoimmunity I. TP-5 suppression of induced erythrocyte autoantibodies in C3H mice. J Immunol 125:1634-1638.
Weksler, Innes, Goldstein (1978) Immunological studies of aging IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin 32-36. J Exp Med 148:996-1006.
Sunshine, Basch, Goffrey, Cohen, Goldstein, Hadden (1978) Thymopoietin enhances the allogenic response and cyclic GMP levels of mouse peripheral thymus-derived lymphocytes. J Immunol 120:1594-1599.
Lau, Goldstein (1980) Functional effects of TP-5 on cytotoxic lymphocyte precursor units (CLP.U) I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulations. J Immunol 124:1861-1865.
Lau, Wang, Goldstein (1982) Effects of thymopoietin pentapeptide on experimental tumors I. TP-5 relieves immunosuppression in tumor-bearing mice. Cell Immunol 66:217-232.
Duchateau, Delespesse, Bolla (1983) Phase variation in the modulation of the human immune response. Immunol Today 4:213-214.
Tischio, Patrick, Weintraub, Chasing, Goldstein (1979) Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. Int J Pept Prot Res 14:479-484.
DiPerri, Laghi Pasini, Auteri (1980) Immunokinetics of a single dose of thymopoietin pentapeptide. Immunopharmacology and Immunotoxicology 2:567-572.
Bolla, Duchateau, Delespesse, Servais Clinical-pharmacological evidence for the immunomodulatory property of thymopentin in elderly volunteers, Bioscience Ediprint Inc, Geneva, Proceedings of the 1st World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Venice (in press); 1984.
Audhya, Goldstein (1983) Comparative efficacy of various routes of administration of thymopentin (TP-5) with considerations of degradative mechanisms. Int J Pept Prot Res 22:187-193.
Audhya, Goldstein (1983) Thymopentin (TP-5) potency in vivo is enhanced by slow infusion. Int J Pept Prot Res 22:568-572.
Janossy, Duke, Paulter, Panayi, Bofill, Goldstein (1981) Rheumatoid arthritis- a disease of T lymphocyte/macrophage immunoregulation. Lancet 2:839-842.
Veys, Hermans, Schindler (1982) Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. J Rheumatol 9:25-29.
Veys, Huskisson, Rosenthal (1982) Clinical responses to therapy with thymopentin (TP-5) in rheumatoid arthritis. Ann Rheum Dis 41:441-443.
Rosenthal, Huskisson, Veys, Vischer (1981) Thymopentin bei der Behandlung der chronischen Polyarthritis. Verth Dtsch Ges Rheumatol 7:400-443.
Horwith, Glynn, Barada (1980) Effects of thymopoietin 32-36 (TP-5) in rheumatoid arthritis: A preliminary report. Immunoregulation and autoimmunity. , Rs Krakauer, Mk Cathcart, Elsevier/North Holland, Amsterdam; 231-240.
Weaver, Churchill, Jacobs (1984) Treatment of refractory rheumatoid arthritis with thymopoietin pentapeptide Abstract. Arthritis Rheum , (suppl); 27:B46.
Veys, Mielants, Verbruggen (1984) Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis A compilation of several short- and long-term clinical studies. J Rheumatol 11:462-466.
Sharpe (1976) HCG-induced decrease in availability of rat testis receptors. Nature(Lond) 264:644-646.
Franchimont, Hauwaert, Bolla Controlled open clinical study with 'Immunox' (TP-5) in the treatment of active rheumatoid arthritis, Documentation CILAG Ltd, Schaffhausen, Switzerland, TPH 01579; 1983.
Cooperating Clinic Committee of American Rheumatism Association Arthritis Rheum 1976, 8:302-310.
Ritchie, Boyle, McInnes (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quart J Med 37:393-406.
Huskisson (1974) Measurement of pain. Lancet 2:1127-1131.
Umbenhauer (1981) Is the ability to detect drug effect in rheumatic diseases increased by measuring more clinical parameters?. Controversies in the clinical evaluation of analgesic-anti-inflammatory-antirheumatic drugs. , He Paulus, Ge Ehrlich, E. Lindenlaub, F. K. Schattaeur, Stuttgart; 193-202.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
